{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:32:10Z","timestamp":1792503130930,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eclinm.2025.103348","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:59:07Z","timestamp":1752616747000},"page":"103348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Measurable residual disease in hematologic malignancies: a biomarker in search of a standard"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-4509","authenticated-orcid":false,"given":"Namrata S.","family":"Chandhok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eclinm.2025.103348_bib1","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2024.2122","article-title":"Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"10","author":"Rios-Olais","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103348_bib5","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib6","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103348_bib7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.V82.6.1689.1689","article-title":"Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML\/RAR-alpha fusion mRNA","volume":"82","author":"Miller","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103348_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/10428194.2021.1992757","article-title":"Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline \u2018chemotherapy-free\u2019 therapy","volume":"63","author":"Ramos Perez","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103348_bib10","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3324\/haematol.2022.281493","article-title":"Measurable residual disease in chronic myeloid leukemia","volume":"107","author":"Branford","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103348_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103348_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/ajh.27604","article-title":"Novel flow cytometric antibody panel and dedicated analysis algorithm for automated fully standardized minimal residual disease detection in chronic lymphocytic leukemia","volume":"100","author":"Engelmann","year":"2025","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103348_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103348_bib15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103348_bib16","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103348_bib17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","article-title":"Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines","volume":"38","author":"van der Velden","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103348_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study","volume":"42","author":"Pott","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103348_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","volume":"24","author":"Br\u00fcggemann","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103348_bib21","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-024-02378-5","article-title":"Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)","volume":"38","author":"Rodr\u00edguez-Arbol\u00ed","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103348_bib22","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib23","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103348_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103348_bib27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-024-01078-8","article-title":"Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: an ALFA study","volume":"14","author":"Hirsch","year":"2024","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103348_bib29","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103348_bib30","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103348_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103348_bib32","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103348_bib33","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2023022540","article-title":"ctDNA improves prognostic prediction for patients with relapsed\/refractory MM receiving ixazomib, lenalidomide, and dexamethasone","volume":"143","author":"Kogure","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103348_bib34","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.leu.2402636","article-title":"Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib35","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103348_bib36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41375-019-0599-1","article-title":"Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia","volume":"34","author":"Kotrova","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103348_bib37","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.eclinm.2025.103348_bib38","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103348_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"12.5","key":"10.1016\/j.eclinm.2025.103348_bib40","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.6004\/jnccn.2020.5034","article-title":"Updates in the management of CLL\/SLL: sequencing therapy and the role of minimal residual disease testing","volume":"18","author":"Wierda","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"issue":"31","key":"10.1016\/j.eclinm.2025.103348_bib42","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103348_bib43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41409-019-0739-2","article-title":"Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"55","author":"Hoffmann","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103348_bib44","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103348_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103348_bib46","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study","volume":"174","author":"Tierens","year":"2016","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103348_bib47","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to \u0394N flow cytometry: a Children's Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103348_bib48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103348_bib49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103348_bib50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103348_bib52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103348_bib53","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103348_bib54","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103348_bib55","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.clml.2022.08.004","article-title":"SOHO state of the art updates and next questions: measurable residual disease in acute lymphoblastic leukemia - optimization and innovation in 2022 and beyond","volume":"22","author":"Dekker","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103348_bib56","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103348_bib57","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103348_bib58","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib59","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib60","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103348_bib61","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103348_bib62","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103348_bib63","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D'Agostino","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103348_bib66","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib67","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","article-title":"Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma","volume":"27","author":"Jakubowiak","year":"2022","journal-title":"Oncologist"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103348_bib68","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103348_bib69","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103348_bib71","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib72","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10388","key":"10.1016\/j.eclinm.2025.103348_bib73","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103348_bib74","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2024-207305","volume":"144","author":"Levis","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103348_bib75","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/1078-0432.CCR-22-3579","article-title":"Minimal residual disease data in hematologic malignancy drug applications and labeling: an FDA perspective","volume":"29","author":"Baines","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103348_bib76","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/hematology.2023000441","article-title":"MRD-directed therapy in CLL: ready for prime time?","volume":"2023","author":"Rhodes","year":"2023","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103348_bib77","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2020.7542","article-title":"Private payer and medicare coverage for circulating tumor DNA testing: a historical analysis of coverage policies from 2015 to 2019","volume":"18","author":"Douglas","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eclinm.2025.103348_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-025-02604-3","article-title":"Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines","author":"Rehman","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.eclinm.2025.103348_bib79","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1182\/blood-2019-123461","article-title":"Education and promotion of MRD testing within the multidisciplinary cancer care Team for adults with acute lymphoblastic leukemia in the community setting","volume":"134","author":"Dawkins","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103348_bib80","article-title":"MM-318 perspectives of single-center community hematologists\/oncologists on minimal residual disease testing among patients with multiple myeloma","volume":"24","author":"Gordan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:09:59Z","timestamp":1755850199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025002809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":77,"alternative-id":["S2589537025002809"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103348","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable residual disease in hematologic malignancies: a biomarker in search of a standard","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103348"}}